DAVID MCLAIN: Open Payments
NPI 1689614737 · BIRMINGHAM, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$222,386 in 212 payments from 21 companies in 2025. Trend: 2023 $78,752 · 2024 $186,852 · 2025 $222,386
Grant: $217,128Food & beverage: $5,108Education: $150
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 47 | $217,890 |
| Amgen Inc. | 44 | $957 |
| Novartis Pharmaceuticals Corporation | 20 | $666 |
| Mallinckrodt Hospital Products Inc. | 13 | $488 |
| GlaxoSmithKline, LLC. | 13 | $392 |
| UCB, Inc. | 18 | $312 |
| PFIZER INC. | 15 | $276 |
| AstraZeneca Pharmaceuticals LP | 9 | $276 |
| Aurinia Pharma U.S., Inc. | 2 | $259 |
| GENZYME CORPORATION | 7 | $239 |
Products named: RINVOQ, COSENTYX, ACTHAR, Bimzelx, SAPHNELO, TAVNEOS, LUPKYNIS, OTEZLA.
Industry payments across AL — which companies pay providers there.
